The community-acquired bacterial pneumonia market is poised for continued growth, driven by the substantial global disease burden, increasing hospitalization rates, an aging population, rising prevalence of comorbidities, and the growing challenge of antimicrobial resistance. Additionally, the launch of emerging therapies such as CAL02 (Eagle Pharmaceutical/Combioxin), AON-D21 (APTARION Biotech), Trimodulin (BT588; Biotest AG), and others will further propel market growth.. 社区获得性细菌性肺炎市场有望持续增长，其驱动因素包括沉重的全球疾病负担、住院率上升、人口老龄化、合并症患病率增加以及抗菌药物耐药性带来的日益严峻的挑战。此外，CAL02（Eagle Pharmaceutical/Combioxin）、AON-D21（APTARION Biotech）、Trimodulin（BT588；Biotest AG）等新兴疗法的上市也将进一步推动市场增长。LAS VEGAS 拉斯维加斯, ，Sept. 7, 2026 2026年9月7日/PRNewswire/ -- Recently published Community-Acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, community-acquired bacterial pneumoniaemerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《社区获得性细菌性肺炎市场洞察》报告全面解析了当前的治疗实践、社区获得性细菌性肺炎新兴药物、各疗法的市场份额，以及2022年至2036年的当前市场规模和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Community-Acquired Bacterial Pneumonia Market Summary 社区获得性细菌性肺炎市场概览The total community-acquired bacterial pneumoniatreatment market size is expected to grow positively by 2036 in the leading markets. 到2036年，主要市场的社区获得性细菌性肺炎治疗市场总规模预计将实现正增长。The United States accounted for the largest community-acquired bacterial pneumoniatreatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 2025年，在七大主要市场（7MM）中，美国占据了最大的社区获得性细菌性肺炎治疗市场规模，其他主要市场包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本。Around 周围80% 80%of the nearly 在将近4 million 400万cases of community-acquired pneumonia (CAP) in the US are classified as CABP. This high prevalence of CABP within the broader category of CAP underscores the significant burden of bacterial pathogens in pneumonia cases. 美国的社区获得性肺炎（CAP）病例被归类为社区获得性细菌性肺炎（CABP）。在更广泛的CAP类别中，CABP的高患病率突显了细菌病原体在肺炎病例中的重大负担。Leading community-acquired bacterial pneumonia companies, such as 社区获得性细菌性肺炎领域的领先企业，例如Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, 鹰牌制药公司，Combioxin公司，APTARION生物技术公司，Biotest股份公司，and others, are developing new community-acquired bacterial pneumonia treatmentdrugs that can be available in the community-acquired bacterial pneumonia market in the coming years. 以及其他公司正在开发新的社区获得性细菌性肺炎治疗药物，这些药物有望在未来几年内上市。The promising community-acquired bacterial pneumonia therapiesin clinical trials include 临床试验中前景广阔的社区获得性细菌肺炎疗法包括CAL02, AON-D21, Trimodulin (BT588), CAL02，AON-D21，Trimodulin（BT588），and others. 以及其他。Discover CABP clinical trial 2026 update press release @ 发现2026年社区获得性细菌性肺炎（CABP）临床试验更新的新闻稿 @https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-marketKey Factors Driving the Growth of the Community-Acquired Bacterial Pneumonia Market 推动社区获得性细菌性肺炎市场增长的关键因素Rising Burden of Community-Acquired Bacterial Pneumonia: 社区获得性细菌性肺炎的负担日益加重：The persistent incidence of community-acquired bacterial pneumonia (CABP), particularly among older adults, children, and individuals with underlying conditions, is driving demand for effective treatment options. The associated morbidity, hospitalization rates, and mortality further support market growth.. 社区获得性细菌性肺炎（CABP）的持续发病率，尤其是在老年人、儿童和患有基础疾病的人群中，正在推动对有效治疗方案的需求。相关的发病率、住院率和死亡率进一步促进了市场增长。Increasing Antimicrobial Resistance: 日益严重的抗菌药物耐药性：The growing prevalence of antibiotic-resistant bacterial pathogens is creating a need for novel antibiotics and therapies with improved efficacy against resistant strains. This is encouraging pharmaceutical companies to invest in the development of next-generation antibacterial treatments. 抗生素耐药性细菌病原体的日益普遍，使得人们迫切需要开发对耐药菌株具有更好疗效的新型抗生素和疗法。这正促使制药公司加大对下一代抗菌治疗药物研发的投入。Advancements in Antibiotic Development: 抗生素研发的进展：Ongoing research into novel antibacterial mechanisms, improved formulations, and targeted therapies is expanding the treatment landscape for CABP. The emergence of differentiated therapies may provide additional options for patients who have limited responses to conventional antibiotics. 针对新型抗菌机制、改良制剂和靶向疗法的持续研究正在拓展社区获得性细菌性肺炎（CABP）的治疗格局。差异化疗法的涌现可能为对传统抗生素反应有限的患者提供额外的治疗选择。Launch of CABP Drugs: 社区获得性细菌性肺炎（CABP）药物上市：The dynamics of the CABP market are expected to change in the coming years due to the launch of emerging therapies such as 由于新兴疗法的推出，预计未来几年CABP市场的动态将发生变化，例如CAL02 CAL02(Eagle Pharmaceutical/Combioxin), （伊格尔制药/Combioxin）AON-D21 AON-D21(APTARION Biotech), （APTARION Biotech），Trimodulin 曲莫杜林(BT588; Biotest AG), and others. (BT588；Biotest AG) 等。Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that emerging candidates such as CAL02 and AON-D21 are being developed to complement conventional antibiotic treatment by targeting bacterial toxins, virulence factors, and host inflammatory responses. These novel approaches aim to improve clinical outcomes in severe CABP and address challenges associated with antimicrobial resistance and treatment failure.. DelveInsight 预测与分析项目经理 Aparna Thakur 表示，CAL02 和 AON-D21 等新兴候选药物正在开发中，旨在通过靶向细菌毒素、毒力因子和宿主炎症反应，作为传统抗生素治疗的补充。这些新颖疗法旨在改善严重社区获得性细菌性肺炎（CABP）患者的临床结局，并应对与抗菌素耐药性和治疗失败相关的挑战。Community-Acquired Bacterial Pneumonia Market Analysis 社区获得性细菌性肺炎市场分析Community-acquired pneumonia continues to represent a substantial global health burden, contributing significantly to both morbidity and mortality. Identifying the optimal antibiotic therapy for CAP, however, remains challenging because of several clinical and epidemiological considerations. 社区获得性肺炎（CAP）仍然构成重大的全球健康负担，显著导致发病率和死亡率。然而，由于多种临床和流行病学因素，确定CAP的最佳抗生素治疗方案仍具挑战性。The treatment landscape is also evolving as the efficacy and safety profiles of established antibiotics change over time. The growing prevalence of antimicrobial resistance has further complicated treatment decisions by reducing the effectiveness of previously reliable therapies against certain pathogens.. 随着既定抗生素的疗效和安全性特征随时间发生变化，治疗格局也在不断演变。抗菌药物耐药性的日益普遍进一步复杂化了治疗决策，因为它降低了以往对某些病原体可靠疗法的有效性。As a result, clinicians must carefully select antibiotic regimens based on local resistance trends, suspected causative pathogens, disease severity, and individual patient characteristics. 因此，临床医生必须根据当地的耐药趋势、疑似致病菌、疾病严重程度以及患者个体特征，谨慎选择抗生素治疗方案。The introduction of newer antibiotics has expanded the therapeutic options available for CAP in recent years. 近年来，新型抗生素的问世扩大了社区获得性肺炎（CAP）的治疗选择。Agents such as 诸如以下代理：omadacycline (NUZYRA), delafloxacin (BAXDELA), and lefamulin (XENLETA) 奥马环素（NUZYRA）、德拉沙星（BAXDELA）和来法莫林（XENLETA）have strengthened the CAP treatment armamentarium, particularly for patients who are unsuitable for or do not adequately respond to conventional therapies. 增强了社区获得性肺炎（CAP）的治疗手段，尤其适用于不适合或对传统疗法反应不足的患者。With broader antimicrobial coverage and, in some cases, novel mechanisms of action, these therapies provide additional options for managing infections caused by a diverse range of CAP pathogens. 凭借更广泛的抗菌谱以及在某些情况下的新颖作用机制，这些疗法为管理由多种社区获得性肺炎（CAP）病原体引起的感染提供了更多选择。Several antibiotics are also approved for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), including 多种抗生素也已获批用于治疗医院获得性细菌性肺炎（HABP）和呼吸机相关性细菌性肺炎（VABP），包括cefiderocol (FETROJA), ceftazidime-avibactam (AVYCAZ), telavancin (VIBATIV) 头孢地罗（FETROJA）、头孢他啶-阿维巴坦（AVYCAZ）、特拉万星（VIBATIV）, and the combination of ，以及……的组合ceftolozane and tazobactam (ZERBAXA) 头孢洛扎和他唑巴坦（ZERBAXA）, among others. ，等等。By comparison, the pipeline for emerging therapies specifically targeting CAP remains relatively limited, although ongoing research and clinical development programs are focused on addressing unmet treatment needs. 相比之下，专门针对社区获得性肺炎（CAP）的新兴疗法研发管线仍然相对有限，尽管当前的研究和临床开发项目正致力于满足尚未被满足的治疗需求。The emerging community-acquired bacterial pneumonia (CABP) pipeline includes candidates such as 新兴的社区获得性细菌性肺炎（CABP）研发管线包括以下候选药物：CAL02 CAL02, developed by Eagle Pharmaceuticals and Combioxin SA, and 由Eagle Pharmaceuticals和Combioxin SA开发，并且AON-D21 AON-D21from APTARION Biotech, among others. 来自APTARION Biotech等公司。These investigational therapies employ innovative approaches aimed at overcoming antimicrobial resistance and improving clinical outcomes, particularly among patients with severe CABP. 这些在研疗法采用创新方法，旨在克服抗菌药物耐药性并改善临床结局，尤其是在患有严重社区获得性细菌性肺炎（CABP）的患者中。Overall, the availability of both established and recently approved antibiotics has broadened the treatment landscape for CAP, including cases associated with complications or resistance concerns. 总体而言，既有抗生素和近期获批抗生素的可及性拓宽了社区获得性肺炎（CAP）的治疗格局，包括与并发症或耐药性问题相关的病例。Commonly used antimicrobial regimens include macrolides, either alone or in combination with β-lactams; amoxicillin as monotherapy or combined with a macrolide; fluoroquinolones; and third-generation cephalosporins administered in combination with a macrolide. 常用的抗菌方案包括：大环内酯类（单用或与β-内酰胺类联用）、阿莫西林（单用或与大环内酯类联用）、氟喹诺酮类，以及第三代头孢菌素联合大环内酯类。Community-Acquired Bacterial Pneumonia Competitive Landscape 社区获得性细菌肺炎竞争格局Some of the CABP drugs under development include 正在研发中的社区获得性细菌性肺炎（CABP）药物包括CAL02 CAL02(Eagle Pharmaceutical/Combioxin), （Eagle Pharmaceutical/Combioxin）AON-D21 AON-D21(APTARION Biotech), （APTARION Biotech）Trimodulin 曲莫杜林(BT588; Biotest AG), and others. （BT588；Biotest AG）等。Eagle Pharmaceutical/Combioxin's CAL02 Eagle Pharmaceutical/Combioxin 的 CAL02is a Phase II-stage therapeutic candidate being developed to address severe infections, particularly community-acquired pneumonia (CAP) among critically ill ICU patients. The treatment consists of liposomes formulated with cholesterol and sphingomyelin, with sphingomyelin incorporated for its distinctive anti-infective properties. 是一种处于II期临床阶段的候选治疗药物，旨在治疗严重感染，特别是重症监护室（ICU）危重患者中的社区获得性肺炎（CAP）。该疗法由含有胆固醇和鞘磷脂的脂质体组成，其中掺入鞘磷脂是利用其独特的抗感染特性。This formulation highlights the therapeutic potential of antimicrobial lipids in combating bacterial infections.. 该制剂突显了抗菌脂质在对抗细菌感染方面的治疗潜力。CAL02 works by neutralizing bacterial virulence effectors, which play a significant role in the development of organ dysfunction and life-threatening complications associated with severe infections. By targeting these virulence mechanisms rather than solely focusing on bacterial eradication, CAL02 aims to limit disease progression and potentially improve clinical outcomes.. CAL02 通过中和细菌毒力效应因子发挥作用，这些效应因子在严重感染相关的器官功能障碍和危及生命的并发症的发展中起着重要作用。CAL02 旨在通过靶向这些毒力机制，而非仅仅专注于清除细菌，来限制疾病进展并可能改善临床结局。The candidate has received 候选人已收到Fast Track and Qualified Infectious Disease Product (QIDP) designations 快速通道认定和合格传染病产品（QIDP）认定from the U.S. FDA. These regulatory designations can provide an additional five years of market exclusivity, potentially extending the total exclusivity period to eight or ten years. 来自美国食品药品监督管理局（FDA）。这些监管认定可提供额外的五年市场独占期，可能将总独占期延长至八年或十年。APTARION Biotech's AON-D21 阿普塔里昂生物科技公司的AON-D21is another therapeutic candidate currently undergoing Phase II clinical development. It is a PEGylated, L-configured aptamer, a synthetic molecule engineered to selectively bind to specific biological targets. AON-D21 is designed to modulate the complement pathway by selectively binding to and neutralizing C5a, a key component of the immune system.. 是另一种目前正在接受II期临床开发的治疗候选药物。它是一种聚乙二醇化、L构型的适配体，这是一种经过工程改造以选择性结合特定生物靶点的合成分子。AON-D21旨在通过选择性结合并中和免疫系统的关键组分C5a来调节补体通路。C5a serves as an important mediator of immune activity and plays a central role in coordinating inflammatory responses. Its broad involvement in immune regulation creates opportunities for C5a-targeted therapies across multiple disease areas, particularly conditions in which excessive or dysregulated immune responses contribute to disease progression.. C5a是免疫活动的重要介质，在协调炎症反应中发挥核心作用。其广泛参与免疫调节，为针对C5a的疗法在多种疾病领域的应用创造了机会，尤其是在那些由过度或失调的免疫反应导致疾病进展的病症中。The anticipated launch of these emerging therapies are poised to transform the CABPmarket landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CABPmarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内改变社区获得性细菌性肺炎（CABP）市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计将重塑 CABP 市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。Discover more about the latest treatments for CABP 2026 @ 探索2026年社区获得性细菌性肺炎（CABP）的最新治疗方案 @Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 社区获得性细菌肺炎治疗药物临床试验Community-Acquired Bacterial Pneumonia Epidemiology Segmentation 社区获得性细菌性肺炎的流行病学细分The CABPepidemiology section provides insights into the historical and current CABPpatient pool and forecasted trends for the leading markets. In the US, mild cases of CABP constituted the highest proportion, approximately CABP流行病学部分提供了对历史和当前CABP患者群体以及主要市场预测趋势的见解。在美国，轻度CABP病例占比最高，约为50% 百分之五十of total incident cases, followed by moderate cases at around 占总病例数的，其次是中等病例，约占35% 百分之三十五. 。The CABPtreatment market reportproffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 《社区获得性细菌性肺炎（CABP）治疗市场报告》提供了2022–2036年研究期间主要市场的流行病学分析，细分如下：Total Incident Cases of CABP 社区获得性细菌性肺炎（CABP）总病例数Gender-specific Cases of CABP 社区获得性细菌性肺炎的性别特异性病例Severity-specific Cases of CABP 按严重程度分类的社区获得性细菌性肺炎病例Pathogen-specific Cases of CABP 社区获得性细菌性肺炎（CABP）的病原体特异性病例Age-specific Cases of CABP 按年龄分组的社区获得性细菌性肺炎病例Total Treated Cases of CABP 社区获得性肺炎（CABP）总治疗病例数Community-Acquired Bacterial Pneumonia Market Report Metrics 社区获得性细菌性肺炎市场报告指标Details 详情Study Period 学习阶段2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 700万 [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Community-Acquired Bacterial Pneumonia Epidemiology Segmentation 社区获得性细菌性肺炎流行病学细分Total Incident Cases of CABP, Gender-specific Cases of CABP, Severity-specific Cases of CABP, Pathogens-specific Cases of CABP, Age-specific Cases of CABP, and Total Treated Cases of CABP 社区获得性细菌性肺炎（CABP）的总病例数、按性别划分的CABP病例数、按严重程度划分的CABP病例数、按病原体划分的CABP病例数、按年龄划分的CABP病例数，以及CABP的总治疗病例数Key Community-Acquired Bacterial Pneumonia Companies 社区获得性细菌性肺炎领域的主要企业Eagle Pharmaceutical, Combioxin, APTARION Biotech, Biotest AG, Nabriva Therapeutics, Paratek Pharmaceutical, and others 鹰制药公司、Combioxin公司、APTARION生物技术公司、Biotest股份公司、Nabriva治疗公司、Paratek制药公司及其他公司KeyCommunity-Acquired Bacterial PneumoniaTherapies 社区获得性细菌性肺炎的主要疗法CAL02, AON-D21, Trimodulin (BT588), XENLETA, NUZYRA, and others CAL02、AON-D21、Trimodulin（BT588）、XENLETA、NUZYRA 等Scope of the 范围Community-Acquired Bacterial Pneumonia 社区获得性细菌性肺炎Market Report 市场报告Community-Acquired Bacterial Pneumonia Patient Population Forecast 社区获得性细菌性肺炎患者人群预测Community-Acquired Bacterial Pneumonia Therapeutics Market Size 社区获得性细菌肺炎治疗药物市场规模Community-Acquired Bacterial Pneumonia Pipeline Analysis 社区获得性细菌性肺炎研发管线分析Community-Acquired Bacterial Pneumonia Market Size and Trends 社区获得性细菌性肺炎市场规模与趋势Community-Acquired Bacterial Pneumonia Market Opportunity 社区获得性细菌性肺炎市场机遇Community-Acquired Bacterial Pneumonia Market Unmet Needs 社区获得性细菌肺炎市场的未满足需求KOL's Views on Community-Acquired Bacterial Pneumonia 关键意见领袖对社区获得性细菌性肺炎的观点Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 社区获得性细菌性肺炎的市场准入与报销Download the report to understand the CABP treatment market@ 下载报告以了解社区获得性细菌性肺炎（CABP）治疗市场Community-Acquired Bacterial Pneumonia Drugs 社区获得性细菌性肺炎药物Table of Contents 目录1 1Community-Acquired Bacterial Pneumonia Market Key Insights 社区获得性细菌性肺炎市场关键洞察2 2Community-Acquired Bacterial Pneumonia Market Report Introduction 社区获得性细菌性肺炎市场报告简介3 3Executive Summary 执行摘要4 4Key Events 关键事件5 5Epidemiology and Market Methodology 流行病学与市场方法论6 6Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance 社区获得性细菌性肺炎（CABP）市场概览6.1 6.1Clinical Landscape Analysis (By Phase, Molecule Type, and RoA) 临床格局分析（按阶段、分子类型和作用机制）6.2 6.2Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2025 2025年七个主要市场（7MM）中按疗法划分的社区获得性细菌性肺炎（CABP）市场份额（%）分布6.3 6.3Market Share (%) Distribution of CABP by Therapies in the 7MM, in 2036 2036年七个主要国家（7MM）社区获得性细菌性肺炎（CABP）按治疗方案划分的市场份额（%）分布7 7Disease Background and Overview 疾病背景与概述7.1 7.1Introduction 引言7.2 7.2Etiology 病因学7.3 7.3Pathophysiology 病理生理学7.4 7.4Signs and Symptoms of CABP 社区获得性细菌性肺炎的体征和症状7.5 7.5Clinical Characteristics 临床特征7.6 7.6Immunology & Risk Factors 免疫学与风险因素7.7 7.7Diagnosis 诊断7.8 7.8Prognosis 预后7.9 7.9Diagnostic Biomarkers for CABP 社区获得性细菌性肺炎（CABP）的诊断生物标志物8 8Treatment and Management 治疗与管理8.1 8.1Antibiotic therapy 抗生素治疗8.2 8.2Diuretics 利尿剂8.3 8.3Corticosteroids 皮质类固醇8.4 8.4Later management 后期管理8.5 8.5Diagnostic and Treatment Guidelines 诊断与治疗指南9 9Epidemiology and Patient Population 流行病学与患者人群9.1 9.1Key Findings 主要发现9.2 9.2Assumptions and Rationale 假设与理由9.3 9.3Total Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the 7MM 七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）的总发病病例数9.4 9.4The United States 美国9.5.1 9.5.1Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的发病病例9.5.2 9.5.2Gender-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的性别特异性病例9.5.3 9.5.3Severity-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的严重程度特异性病例9.5.4 9.5.4Pathogen-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的病原体特异性病例9.5.5 9.5.5Age-specific Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）的年龄别病例数9.5.6 9.5.6Total treated Cases of Community-Acquired Bacterial Pneumonia (CABP) 社区获得性细菌性肺炎（CABP）治疗病例总数9.6 9.6EU4 and the UK 欧盟四国与英国9.7 9.7Japan 日本10 10Patient Journey 患者旅程11 十一Marketed CABP Therapies 已上市的社区获得性细菌性肺炎（CABP）治疗药物11.1 11.1Marketed Competitive Landscape 市场竞争格局11.2 11.2Lefamulin (XENLETA): Nabriva Therapeutics lefamulin（XENLETA）：Nabriva Therapeutics11.2.1 11.2.1Drug Description 药物说明11.2.2 11.2.2Regulatory Milestones 监管里程碑11.2.3 11.2.3Other Developmental Activities 其他发展性活动11.2.4 11.2.4Summary of Pivotal Trials 关键试验总结11.2.5 11.2.5Clinical Development 临床开发11.2.5.1 11.2.5.1Clinical Trial Information 临床试验信息11.2.6 11.2.6Safety and Efficacy 安全性与有效性11.2.7 11.2.7Analyst's Views 分析师观点11.3 11.3Omadacycline (NUZYRA): Paratek Pharmaceuticals 奥马环素（NUZYRA）：Paratek PharmaceuticalsList will be continued in the report… 列表将在报告中继续……12 十二Emerging CABP Drugs 新兴的社区获得性细菌性肺炎（CABP）药物12.1 12.1Emerging Competitive Landscape 新兴竞争格局12.2 12.2CAL02: Eagle Pharmaceutical/Combioxin SA CAL02：伊格尔制药/Combioxin SA12.2.1 12.2.1Drug Description 药物说明12.2.2 12.2.2Other Developmental Activities 其他发展性活动12.2.3 12.2.3Clinical Development 临床开发12.2.3.1 12.2.3.1Clinical Trials Information 临床试验信息12.2.4 12.2.4Safety and Efficacy 安全性与有效性12.2.5 12.2.5Analyst's Views 分析师观点12.3 12.3AON-D21 (anti-C5a): APTARION Biotech AG AON-D21（抗C5a）：APTARION Biotech AGList will be continued in the report… 列表将在报告中继续……13 13Other Therapies: Generics 其他疗法：仿制药13.1 13.1Amoxicillin 阿莫西林13.2 13.2Azithromycin 阿奇霉素13.3 13.3Clarithromycin 克拉霉素13.4 13.4Doxycycline 多西环素13.5 13.5Moxifloxacin 莫西沙星13.6 13.6Vaccine 疫苗14 14Community-Acquired Bacterial Pneumonia Market: 7MM Analysis 社区获得性细菌性肺炎市场：七国市场分析14.1 14.1Key Findings 主要发现14.2 14.2Community-Acquired Bacterial Pneumonia Market Outlook 社区获得性细菌性肺炎市场前景14.3 14.3Conjoint analysis 联合分析14.4 14.4Key Community-Acquired Bacterial Pneumonia Market Forecast Assumptions 社区获得性细菌性肺炎市场预测的关键假设14.5 14.5Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM 七大主要市场社区获得性细菌性肺炎（CABP）的总体市场规模14.6 14.6Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM 七大主要市场（7MM）中社区获得性细菌性肺炎（CABP）按疗法划分的市场规模14.7 14.7The United States CABP Market Size 美国社区获得性细菌性肺炎（CABP）市场规模14.7.1 14.7.1Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States 美国社区获得性细菌性肺炎（CABP）的总体市场规模14.7.2 14.7.2Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States 美国社区获得性细菌性肺炎（CABP）按疗法划分的市场规模14.8 14.8EU4 and the UK CABP Market 欧盟4国及英国CABP市场14.9 14.9Japan CABP Market Size 日本社区获得性细菌性肺炎（CABP）市场规模15 十五KOL Views KOL观点16 十六Unmet Needs 未满足的需求17 17SWOT Analysis SWOT分析18 十八CABP Market Access and Reimbursement 社区获得性细菌性肺炎（CABP）的市场准入与报销19 十九Bibliography 参考文献20 二十Community-Acquired Bacterial Pneumonia Market Report Methodology 社区获得性细菌性肺炎市场报告方法论Related Reports 相关报告Community-Acquired Bacterial Pneumonia Clinical Trial Analysis 社区获得性细菌性肺炎临床试验分析Community-Acquired Bacterial Pneumonia Pipeline – 2026 社区获得性细菌性肺炎研发管线 – 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the keyCABP companies, including 报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键社区获得性细菌性肺炎（CABP）企业的全面洞察，包括Mesoblast, Taiwan Liposome Company, Biosplice, Centrexion Therapeutics, Latigo Biotherapeutics, Pacira BioSciences, Contineum Therapeutics, Tris Pharma, Flexion, Taisho Pharmaceutical, Bioventus, Mesoblast、台湾脂质体公司、Biosplice、Centrexion Therapeutics、Latigo Biotherapeutics、Pacira BioSciences、Contineum Therapeutics、Tris Pharma、Flexion、大正制药、Bioventus，and others. 以及其他。Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market 医院获得性和呼吸机相关性细菌性肺炎市场Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia 医院获得性及呼吸机相关性细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– 2036 – 2036report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and keyHABP/VABP companies, including 报告提供对疾病的深入理解、历史及预测流行病学，以及市场趋势、市场驱动因素、市场障碍和关键HABP/VABP公司，包括Basilea, Merck, Shionogi, Pfizer, Aridis Pharmaceuticals, Polyphor, Aerucin, Motif Bio, 巴塞尔大学、默克、盐野义、辉瑞、Aridis Pharmaceuticals、Polyphor、Aerucin、Motif Bio，and others. 以及其他。Pneumonia Market 肺炎市场Pneumonia Market Insights, Epidemiology, and Market Forecast – 2036 肺炎市场洞察、流行病学及市场预测 – 2036report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pneumonia companies including 报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和包括在内的关键肺炎企业Aridis Pharmaceuticals, Aptarion Biotech, Biotest AG, Vaxcyte, Inc., CanSinoBIO, Inventprise, BioVersys, Aridis Pharmaceuticals，Aptarion Biotech，Biotest AG，Vaxcyte, Inc.，康希诺生物，Inventprise，BioVersys，and others. 以及其他。Bacterial Pneumonia 细菌性肺炎Market 市场Bacterial Pneumonia 细菌性肺炎Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bacterial pneumoniacompanies including 本报告深入剖析了疾病概况、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和细菌性肺炎领域的主要企业，包括Pfizer, Forecast Laboratories, Melinta Therapeutics Inc., Merck Sharp & Dohme LLC, Melinta Therapeutics Inc., Evopoint Biosciences Inc., Paratek Pharmaceuticals Inc., Wockhardt, Clarametyx Biosciences Inc., AstraZeneca, Cumberland Pharmaceuticals, Eagle Pharmaceuticals Inc., Bayer 辉瑞公司、Forecast Laboratories、Melinta Therapeutics Inc.、默沙东有限责任公司、Melinta Therapeutics Inc.、Evopoint Biosciences Inc.、Paratek Pharmaceuticals Inc.、Wockhardt、Clarametyx Biosciences Inc.、阿斯利康、Cumberland Pharmaceuticals、Eagle Pharmaceuticals Inc.、拜耳, ，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案来帮助制药公司提升绩效。通过我们基于订阅的平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us 联系我们Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [emailprotected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight Business Research, LLP21 二十一% 百分之more press release views with 更多新闻稿浏览量，借助Request a Demo 申请演示
